

Shimin Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1010030/publications.pdf>

Version: 2024-02-01

151
papers

6,027
citations

136740

32
h-index

79541

73
g-index

154
all docs

154
docs citations

154
times ranked

5848
citing authors

#	ARTICLE	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	3.3	1,211
2	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
3	I-FLICE, a Novel Inhibitor of Tumor Necrosis Factor Receptor-1- and CD-95-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 1997, 272, 17255-17257.	1.6	363
4	TIPE2, a Negative Regulator of Innate and Adaptive Immunity that Maintains Immune Homeostasis. <i>Cell</i> , 2008, 133, 415-426.	13.5	317
5	A Novel Family of Viral Death Effector Domain-containing Molecules That Inhibit Both CD-95- and Tumor Necrosis Factor Receptor-1-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 1997, 272, 9621-9624.	1.6	298
6	Cellular Inhibitor of Apoptosis 1 and 2 Are Ubiquitin Ligases for the Apoptosis Inducer Smac/DIABLO. <i>Journal of Biological Chemistry</i> , 2003, 278, 10055-10060.	1.6	208
7	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	0.6	206
8	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. <i>Blood</i> , 2016, 127, 2742-2750.	0.6	145
9	Caspase-14 Is a Novel Developmentally Regulated Protease. <i>Journal of Biological Chemistry</i> , 1998, 273, 29648-29653.	1.6	126
10	dFADD, a Novel Death Domain-containing Adapter Protein for the <i>Drosophila</i> Caspase DREDD. <i>Journal of Biological Chemistry</i> , 2000, 275, 30761-30764.	1.6	116
11	Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. <i>Journal of Hematology and Oncology</i> , 2015, 8, 65.	6.9	102
12	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416.	0.8	93
13	cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. <i>Journal of Clinical Investigation</i> , 2005, 116, 174-181.	3.9	91
14	The USP19 Deubiquitinase Regulates the Stability of c-IAP1 and c-IAP2. <i>Journal of Biological Chemistry</i> , 2011, 286, 35380-35387.	1.6	75
15	Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. <i>American Journal of Hematology</i> , 2014, 89, 813-818.	2.0	66
16	Prognostic Factors of Hepatosplenic T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 676-688.	2.1	65
17	Triple-hit B-cell Lymphoma With <i>MYC</i> , <i>BCL2</i> , and <i>BCL6</i> Translocations/Rearrangements. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1132-1139.	2.1	64
18	ALK-positive Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 25-38.	2.1	64

#	ARTICLE	IF	CITATIONS
19	Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. <i>Oncotarget</i> , 2015, 6, 25061-25073.	0.8	58
20	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. <i>British Journal of Haematology</i> , 2017, 178, 403-412.	1.2	57
21	DEDD and DEDD2 associate with caspase-8/10 and signal cell death. <i>Oncogene</i> , 2003, 22, 291-297.	2.6	56
22	Characterization of TNFRSF19, a Novel Member of the Tumor Necrosis Factor Receptor Superfamily. <i>Genomics</i> , 1999, 62, 103-107.	1.3	52
23	Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. <i>Blood</i> , 2015, 126, 1699-1706.	0.6	52
24	MYC Cytogenetic Status Correlates With Expression and Has Prognostic Significance in Patients With MYC/BCL2 Protein Double-positive Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1250-1258.	2.1	51
25	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. <i>American Journal of Surgical Pathology</i> , 2016, 40, 253-261.	2.1	51
26	Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas. <i>Human Pathology</i> , 2012, 43, 1789-1798.	1.1	49
27	Mantle Cell Lymphoma With MYC Rearrangement. <i>American Journal of Surgical Pathology</i> , 2017, 41, 216-224.	2.1	48
28	Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. <i>European Journal of Haematology</i> , 2017, 98, 415-421.	1.1	41
29	Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. <i>Leukemia</i> , 2017, 31, 585-592.	3.3	41
30	Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. <i>Blood Cancer Journal</i> , 2017, 7, e583-e583.	2.8	40
31	Chronic Myeloid Leukemia: Beyond BCR-ABL1. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 435-445.	1.2	38
32	Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. <i>Blood Advances</i> , 2017, 1, 2541-2552.	2.5	37
33	Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. <i>Haematologica</i> , 2017, 102, 1511-1518.	1.7	35
34	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. <i>Blood Advances</i> , 2018, 2, 1807-1816.	2.5	34
35	Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature. <i>Human Pathology</i> , 2016, 58, 72-77.	1.1	33
36	Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. <i>Leukemia</i> , 2015, 29, 2263-2266.	3.3	32

#	ARTICLE	IF	CITATIONS
37	Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 32.	6.9	30
38	<i>De Novo MYC</i> and <i>BCL2</i> Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis. <i>Pediatric Hematology and Oncology</i> , 2015, 32, 535-547.	0.3	30
39	Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. <i>Leukemia</i> , 2016, 30, 1606-1609.	3.3	29
40	8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. <i>Leukemia Research</i> , 2018, 66, 73-78.	0.4	29
41	Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. <i>Leukemia Research</i> , 2018, 73, 86-94.	0.4	29
42	Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline <i>DDX41</i> mutation. <i>American Journal of Hematology</i> , 2020, 95, 227-229.	2.0	29
43	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. <i>Modern Pathology</i> , 2015, 28, 373-382.	2.9	28
44	Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e115-e118.	0.2	27
45	CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. <i>Modern Pathology</i> , 2015, 28, 787-798.	2.9	27
46	Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 441-447.	2.0	26
47	Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases. <i>Cancers</i> , 2021, 13, 878.	1.7	26
48	Myeloid neoplasms with concurrent <i>BCRÁABL1</i> and <i>CBFB</i> rearrangements: A series of 10 cases of a clinically aggressive neoplasm. <i>American Journal of Hematology</i> , 2017, 92, 520-528.	2.0	23
49	Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. <i>Modern Pathology</i> , 2018, 31, 1141-1154.	2.9	23
50	Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults. <i>Annals of Hematology</i> , 2019, 98, 1149-1157.	0.8	23
51	CIAP2 Inhibits Anigen Receptor Signaling by Targeting Bcl10 for Degredation. <i>Cell Cycle</i> , 2006, 5, 1438-1442.	1.3	20
52	Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. <i>Human Pathology</i> , 2019, 85, 290-298.	1.1	19
53	The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. <i>Modern Pathology</i> , 2016, 29, 444-451.	2.9	18
54	Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. <i>Cancer</i> , 2018, 124, 3849-3855.	2.0	18

#	ARTICLE	IF	CITATIONS
55	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. <i>Annals of Diagnostic Pathology</i> , 2019, 41, 38-42.	0.6	18
56	t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 343-351.	1.2	16
57	Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 882-887.	2.0	14
58	Coactivation of NF- κ B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. <i>Blood</i> , 2020, 135, 108-120.	0.6	14
59	T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. <i>Leukemia</i> , 2020, 34, 2509-2512.	3.3	14
60	Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 346-360.	0.8	14
61	Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant. <i>American Journal of Clinical Pathology</i> , 2015, 144, 78-86.	0.4	13
62	Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. <i>Blood Cancer Journal</i> , 2016, 6, e490-e490.	2.8	13
63	Bone marrow findings in blast phase of polycythemia vera. <i>Annals of Hematology</i> , 2018, 97, 425-434.	0.8	13
64	Early detection of transformation to BPDCN in a patient with MDS. <i>Experimental Hematology and Oncology</i> , 2018, 7, 26.	2.0	13
65	Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. <i>Cancer Genetics</i> , 2019, 233-234, 21-31.	0.2	13
66	<i>MET</i> amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 12959-12970.	0.8	13
67	Isolated +15 in bone marrow: Disease-associated or a benign finding?. <i>Leukemia Research</i> , 2015, 39, 72-76.	0.4	12
68	Immunophenotypic Shifts in Primary Cutaneous $\hat{3}\hat{1}$ T-Cell Lymphoma Suggest Antigenic Modulation. <i>American Journal of Surgical Pathology</i> , 2017, 41, 431-445.	2.1	12
69	Tetraploidy/near-tetraploidy acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 53, 20-27.	0.4	12
70	Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. <i>Modern Pathology</i> , 2021, 34, 1143-1152.	2.9	12
71	Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. <i>Human Pathology</i> , 2018, 82, 215-231.	1.1	11
72	Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2831-2838.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases. <i>American Journal of Hematology</i> , 2015, 90, E146-8.	2.0	10
74	Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. <i>Blood Cancer Journal</i> , 2016, 6, e418-e418.	2.8	10
75	Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors. <i>Cancer Genetics</i> , 2018, 228-229, 41-46.	0.2	10
76	Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia?. <i>Cancer Medicine</i> , 2019, 8, 4093-4099.	1.3	10
77	CSF1R inhibition disrupts the dialog between leukaemia cells and macrophages and delays leukaemia progression. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13115-13128.	1.6	10
78	MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naïve Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e512-e518.	1.1	10
79	Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. <i>Blood Cancer Journal</i> , 2020, 10, 86.	2.8	10
80	Clinical significance of acquired loss of the X chromosome in bone marrow. <i>Leukemia Research</i> , 2016, 47, 109-113.	0.4	9
81	Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. <i>Blood Cancer Journal</i> , 2017, 7, e521-e521.	2.8	9
82	HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients. <i>Aids</i> , 2020, 34, 1735-1743.	1.0	9
83	CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. <i>Human Pathology</i> , 2020, 98, 1-9.	1.1	9
84	Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 752-753.	2.0	8
85	Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. <i>Modern Pathology</i> , 2016, 29, 727-734.	2.9	8
86	Copper deficiency-related bone marrow changes secondary to long-term total parenteral nutrition. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 195-196.	0.2	8
87	Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2019, 60, 2993-3001.	0.6	8
88	Follicular Dendritic Cell Sarcoma With Co-Expression of CD4 and CD30 Mimics Anaplastic Large Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 876.	1.3	8
89	iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53 mutation and dismal outcome. <i>Modern Pathology</i> , 2020, 33, 1389-1397.	2.9	8
90	Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2022, 14, 3375.	1.7	8

#	ARTICLE	IF	CITATIONS
91	Chronic myelogenous leukemia in patients with <i>MPL</i> or <i>JAK2</i> mutationâ€positive myeloproliferative neoplasm. <i>International Journal of Laboratory Hematology</i> , 2015, 37, e150-2.	0.7	7
92	Lymphomatous variant of hairy cell leukaemia: a distinctive presentation mimicking lowâ€grade Bâ€cell lymphoma. <i>Histopathology</i> , 2015, 67, 740-745.	1.6	7
93	MYC/BCL2 double-hit lymphoma/leukemia mimicking acute leukemia at initial presentation. <i>Blood</i> , 2016, 127, 1072-1072.	0.6	7
94	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. <i>Modern Pathology</i> , 2021, 34, 327-335.	2.9	7
95	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 338-344.	0.2	7
96	Metastatic Splenic Angiosarcoma Presenting With Thrombocytopenia and Bone Marrow Fibrosis Mimicking Idiopathic Thrombocytopenic Purpura and Primary Myelofibrosis: A Diagnostic Challenge. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 629-633.	0.2	6
97	Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. <i>Annals of Hematology</i> , 2017, 96, 501-504.	0.8	6
98	Clinical significance of isolated del(7p) in myeloid neoplasms. <i>Leukemia Research</i> , 2017, 55, 18-22.	0.4	6
99	3q26/ EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. <i>Leukemia Research</i> , 2018, 65, 25-28.	0.4	6
100	Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. <i>Modern Pathology</i> , 2021, 34, 300-313.	2.9	6
101	t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. <i>Annals of Hematology</i> , 2020, 99, 487-500.	0.8	6
102	3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Modern Pathology</i> , 2017, 30, 940-951.	2.9	5
103	Postchemotherapy Histiocyte-rich Pseudotumor Mimicking Residual Lymphoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 160-168.	2.1	5
104	Philadelphia chromosomeâ€negative acute leukemia in patients with chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E256-E259.	2.0	4
105	Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors. <i>Cancer Genetics</i> , 2020, 241, 57-60.	0.2	4
106	Mutational landscape and its clinical significance in paroxysmal nocturnal hemoglobinuria. <i>Blood Cancer Journal</i> , 2021, 11, 58.	2.8	4
107	Philadelphia chromosome-negative acute myeloid leukemia with 11q23/MLL translocation in a patient with chronic myelogenous leukemia. <i>Stem Cell Investigation</i> , 2015, 2, 13.	1.3	4
108	Composite Classic Hodgkin Lymphoma and Follicular Lymphoma. <i>American Journal of Surgical Pathology</i> , 2022, Publish Ahead of Print, .	2.1	4

#	ARTICLE	IF	CITATIONS
109	Adult acute myeloid leukemia patients with <i>NUP98</i> rearrangement have frequent cryptic translocations and unfavorable outcome. <i>Leukemia and Lymphoma</i> , 2022, 63, 1907-1916.	0.6	4
110	Cup-like blasts in B-lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 596-596.	1.2	3
111	Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse. <i>Blood</i> , 2017, 130, 1483-1483.	0.6	3
112	Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. <i>Data in Brief</i> , 2019, 24, 104025.	0.5	3
113	Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome. <i>Experimental and Molecular Pathology</i> , 2021, 118, 104572.	0.9	3
114	EBV-high-grade B cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements: a multi-institutional study. <i>Histopathology</i> , 2022, 80, 575-588.	1.6	3
115	Constitutional pericentric inversion of chromosome 9 has no impact on survival in chronic myelogenous leukemia. <i>Annals of Hematology</i> , 2016, 95, 657-659.	0.8	2
116	T-lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy: a report of 14 cases. <i>International Journal of Laboratory Hematology</i> , 2017, 39, e45-e50.	0.7	2
117	Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis. <i>Modern Pathology</i> , 2020, 33, 2035-2045.	2.9	2
118	Indolent EBV-positive T-cell lymphoproliferative disorder arising in a chronic pericardial hematoma: the T-cell counterpart of fibrin-associated diffuse large B-cell lymphoma?. <i>Haematologica</i> , 2020, 105, e437-e439.	1.7	2
119	Leukemic phase of Richter transformation: A mimic of acute myeloid leukemia that responded to lbrutinib monotherapy. <i>American Journal of Hematology</i> , 2020, 95, 1221-1223.	2.0	2
120	Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity. <i>Leukemia and Lymphoma</i> , 2022, 63, 235-238.	0.6	2
121	Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution. <i>Leukemia Research</i> , 2021, 111, 106685.	0.4	2
122	Mixed Phenotype Blast Phase of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy. <i>Blood</i> , 2016, 128, 5438-5438.	0.6	2
123	Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. <i>Cancer Genetics</i> , 2022, 262-263, 23-29.	0.2	2
124	Tripartite components of a hepatocellular carcinoma with distinct immunohistochemical and metastatic features. <i>Connecticut Medicine</i> , 2010, 74, 79-83.	0.2	2
125	CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with <i>inv(16)</i> , but patients have higher risk of relapse and may require stem cell transplant. <i>Annals of Hematology</i> , 2022, 101, 847-854.	0.8	2
126	EBV+ ALK+ large B-cell lymphoma. <i>Blood</i> , 2021, 138, 2741-2741.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Cytokeratinâ€positive follicular dendritic cell sarcoma: A mimic of carcinoma. <i>EJHaem</i> , 2022, 3, 254-255.	0.4	2
128	Mastocytosis causing refractory hypotension after coronary angiography. <i>International Journal of Cardiology</i> , 2012, 156, e43-e44.	0.8	1
129	Clinical Significance of Acquired Cytogenetic Clones in Patients With Treated Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 262-269.	0.2	1
130	Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. <i>Bone Marrow Transplantation</i> , 2017, 52, 634-637.	1.3	1
131	<i><i><sc>BCR</sc>â€<sc>ABL</sc>1</i></i> â€negative acute myeloid leukaemia relapsing as <i><i><sc>BCR</sc>â€<sc>ABL</sc>1</i></i> â€positive disease. <i>British Journal of Haematology</i> , 2017, 176, 514-514.	1.2	1
132	51. Clonal size of ALK rearrangements detected by FISH is associated with the duration of progression free survival in metastatic lung cancer treated with ALK inhibitors. <i>Cancer Genetics</i> , 2019, 233-234, S20.	0.2	1
133	Genotypeâ€phenotype correlation of unusual BCRâ€ABL1 transcripts in Philadelphia chromosomeâ€positive leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e207-e211.	1.2	1
134	Incidental but rapidly progressing Tâ€cell polymphocytic leukemia with t(X;14)(q28;q11) involving parotid lymphoepithelial cysts: A diagnostic pitfall. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	1
135	Cytogenetic alterations in CML: not all created equal. <i>Oncotarget</i> , 2018, 9, 11885-11886.	0.8	1
136	Acute Respiratory Distress Syndrome in a Patient With Acute Promyelocytic Leukemia: Overlapping Between Differentiation Syndrome and COVID-19. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 217-220.	0.4	1
137	The many faces of plasma cell neoplasms: morphological and immunophenotypical variants of the great imitator. <i>Pathology</i> , 2022, 54, 32-42.	0.3	1
138	Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?. <i>Frontiers in Oncology</i> , 2021, 11, 795330.	1.3	1
139	Chapter 13 Ubiquitination Mediated by Inhibitor of Apoptosis Proteins. <i>Methods in Enzymology</i> , 2008, 446, 225-235.	0.4	0
140	Neoplastic plasma cells mimic mature neutrophils in plasma cell myeloma with t(11;14)(q13;q32). <i>Blood</i> , 2015, 125, 2875-2875.	0.6	0
141	Diagnostic Utility of the Bone Marrow Core Biopsy in Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S306-S307.	0.2	0
142	MPN-400: Exploring the Molecular Grey Zone of Myeloid Neoplasms: Concurrent SRSF2 and Classic MPN Driver Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S340.	0.2	0
143	Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation. <i>Blood</i> , 2020, 135, 1506-1506.	0.6	0
144	Massâ€forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e135-e137.	0.7	0

#	ARTICLE	IF	CITATIONS
145	Clinicopathologic Features of Myelodysplastic Syndromes Involving Lymph Nodes. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 930-938.	2.1	0
146	Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. Blood, 2016, 128, 1220-1220.	0.6	0
147	Characteristics and outcomes of primary plasma cell leukemia in the era of novel agents: Single center experience.. Journal of Clinical Oncology, 2018, 36, 8054-8054.	0.8	0
148	Chronic Myeloid Leukemia. , 2020, , 501-516.		0
149	Myeloid neoplasms with 8q24/ <i>MYC</i> rearrangement are frequently associated with myelodysplasia, complex karyotype, <i>TP53</i> alterations, and inferior survival. British Journal of Haematology, 0, , .	1.2	0
150	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Modern Pathology, 0, , .	2.9	0
151	Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. Pathology, 2022, , .	0.3	0